GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cardax Inc (OTCPK:CDXI) » Definitions » Margin of Safety % (DCF Earnings Based)

Cardax (Cardax) Margin of Safety % (DCF Earnings Based) : N/A (As of May. 17, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Cardax Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Cardax's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.


Competitive Comparison of Cardax's Margin of Safety % (DCF Earnings Based)

For the Biotechnology subindustry, Cardax's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cardax's Margin of Safety % (DCF Earnings Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cardax's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Cardax's Margin of Safety % (DCF Earnings Based) falls into.



Cardax Margin of Safety % (DCF Earnings Based) Related Terms

Thank you for viewing the detailed overview of Cardax's Margin of Safety % (DCF Earnings Based) provided by GuruFocus.com. Please click on the following links to see related term pages.


Cardax (Cardax) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cardax Inc (OTCPK:CDXI) » Definitions » Margin of Safety % (DCF Earnings Based)
Traded in Other Exchanges
N/A
Address
2800 Woodlawn Drive, Suite 129, Honolulu, HI, USA, 96822
Cardax Inc is a life sciences company engaged in the development of marketing, and distribution of consumer health products in the United States. The firm's platform has applications in arthritis, metabolic syndrome, liver disease, and cardiovascular disease, as well as macular degeneration and prostate disease. It is focused on the development of astaxanthin technologies. The group's product ZanthoSyn is marketed as a novel astaxanthin dietary supplement. Astaxanthin is a clinically studied ingredient with a safe anti-inflammatory activity that supports joint health, cardiovascular health, metabolic health, and liver health. Geographically, it generates maximum revenue from the United States.
Executives
Paulson Capital Corp 10 percent owner 222 THIRD STREET, SUITE 2241, CAMBRIDGE MA 02142
Paulson Investment Company, Inc. 10 percent owner 5335 MEADOWS ROAD SUITE 465 LAKE OSWEGO OR 97035
Paulson Cardax Investments 1 Llc 10 percent owner 811 SW NAITO PKWY SUITE 300 PORTLAND OR 97204

Cardax (Cardax) Headlines

From GuruFocus

Cardax Reports Q1 2018 Results

By PRNewswire PRNewswire 05-09-2018

Cardax Reports Q2 2018 Results

By PRNewswire PRNewswire 08-15-2018

Cardax Announces Interim Results from CHASE Clinical Trial

By PRNewswire PRNewswire 09-23-2019

Cardax Reports Q2 2020 Results

By PRNewswire PRNewswire 08-15-2020

Cardax Reports Q3 2018 Results

By PRNewswire PRNewswire 11-14-2018

Cardax Reports Q3 2020 Results

By PRNewswire PRNewswire 11-14-2020

Cardax Reports Q1 2020 Results

By PRNewswire PRNewswire 05-16-2020